Reslizumab was shown to be effective for patients with chronic sinusitis and nasal polyps in an analysis of two clinical trials.

These patients have an “unusual constellation of symptoms” and are very high users of healthcare, said Steven Weinstein, MD, director of the Allergy and Asthma Specialists Medical Group in Huntington Beach, California.

“Interleukin-5 is a major player in eosinophilic inflammation, and the study patients had high eosinophils and also severe asthma that was uncontrolled with high doses of conventional medications,” he explained here at the American Academy of Allergy, Asthma and Immunology 2016 Annual Meeting.

“This population had a very strong response in terms of decreasing exacerbations and improving lung function and a variety of quality-of-life measures,” Dr Weinstein told Medscape Medical News.

View the full story at